L19TNF plus chemo for returning IDH-mutant brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination therapy (L19TNF plus a chemotherapy drug like temozolomide or lomustine) for people whose IDH-mutant astrocytoma or oligodendroglioma has returned after earlier chemotherapy. The goal is to see if this combination slows tumor growth safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your brain tumor must have an IDH mutation (found in previous genetic testing).
- You've already had chemotherapy (like temozolomide or lomustine) and your tumor has come back or grown.
- You have either an oligodendroglioma or an astrocytoma (WHO grade 2 or higher).
- You need measurable tumor on an MRI scan (using RANO 2.0 criteria).
- You must be 18 or older and in generally good health to handle the treatment.
- You must not be pregnant, and if able to have children, you must use effective birth control for several months during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This study tests a combination of two drugs (vorasidenib and lomustine) for people with a specific type of recurrent brain tumor that has an IDH mutation. The goal is to see if this combination can slow tumor growth better than standard treatments.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.